Biomics

Biomics Biotechnologies Co., Ltd. is a company specializing in the research and industrialization of small nucleic acid drugs. It has eight product lines of small nucleic acid drugs under development, targeting hepatitis, liver cancer, age-related macular degeneration, hyperpigmentation skin diseases, nasopharyngeal cancer, bladder cancer, and cervical cancer. Breakthrough progress has been achieved in the drug for treating hepatitis. The company has developed over a thousand research reagents and technical services. In terms of consumer products, in collaboration with Jiangsu Jikang Bio (a subsidiary partially owned by Biomics), it was the first in the world to launch small nucleic acid-based whitening and freckle-removal skincare products, validating Nobel Prize-winning mechanisms, filling domestic and international gaps, and seizing the high ground of industrialization. These products also include nucleic acid-based acne treatments and cervical cancer diagnostic reagents. All the above products are self-developed patented products.